|
|
|
|
| LEADER |
01690nam a2200301 u 4500 |
| 001 |
EB001839793 |
| 003 |
EBX01000000000000001003782 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Attention-deficit/hyperactivity disorder medication switching for patients with aggression or mood changes secondary to current medication
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|
| 246 |
3 |
1 |
|a ADHD medication switching
|
| 260 |
|
|
|a [Ottawa]
|b Canadian Agency for Drugs and Technologies in Health
|c 2015, 14 September 2015
|
| 300 |
|
|
|a 1 PDF file (14 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Attention Deficit Disorder with Hyperactivity / drug therapy
|
| 653 |
|
|
|a Drug Substitution
|
| 653 |
|
|
|a Central Nervous System Stimulants / adverse effects
|
| 653 |
|
|
|a Guidelines as Topic
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report : summary with critical appraisal
|
| 500 |
|
|
|a Title from PDF caption
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK321366
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to identify the clinical effectiveness, safety, and evidence-based guidelines regarding switching medications in patients with ADHD who experience aggression or mood changes secondary to treatment with common first-line pharmacological treatments
|